SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

SHP656 is the first factor VIII (FVIII) product developed using polysialylation (PSA) technology, in which full‐length recombinant (r) FVIII (anti‐haemophilic factor [recombinant]) is conjugated with a 20 kDa PSA polymer.

[1]  F. Horling,et al.  Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[2]  C. Hermans,et al.  Practical aspects of extended half-life products for the treatment of haemophilia , 2018, Therapeutic advances in hematology.

[3]  P. Lenting,et al.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. , 2016, Blood.

[4]  B. Abbuehl,et al.  Efficacy and safety of pegylated full‐length recombinant factor VIII with extended half‐life for perioperative haemostasis in haemophilia A patients , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  E. Berntorp,et al.  Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products , 2016, Seminars in Thrombosis & Hemostasis.

[6]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[7]  M. Wolfsegger,et al.  Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys , 2015 .

[8]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[9]  A. Tiede,et al.  Half‐life extended factor VIII for the treatment of hemophilia A , 2015, Journal of thrombosis and haemostasis : JTH.

[10]  S. Deyev,et al.  Chemical Polysialylation of Recombinant Human Proteins. , 2015, Methods in molecular biology.

[11]  M. Wolfsegger,et al.  Adjustment of endogenous concentrations in pharmacokinetic modeling , 2014, European Journal of Clinical Pharmacology.

[12]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[13]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[14]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[15]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[17]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[18]  G. Spotts,et al.  Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.

[19]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[20]  H. Platokouki,et al.  Comparative study of validity of clinical, X‐ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  G. Gregoriadis,et al.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.

[22]  P. Toutain,et al.  Plasma terminal half-life. , 2004, Journal of veterinary pharmacology and therapeutics.

[23]  K. Gough,et al.  Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .

[24]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[25]  L. Laliberte,et al.  The Karnofsky performance status scale: An examination of its reliability and validity in a research setting , 1984, Cancer.

[26]  D. Green,et al.  Proceedings: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.

[27]  Masoud Parsania,et al.  THE PATIENTS , 1982, California state journal of medicine.